These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 21193695

  • 1. Induction of Ca²+-driven apoptosis in chronic lymphocytic leukemia cells by peptide-mediated disruption of Bcl-2-IP3 receptor interaction.
    Zhong F, Harr MW, Bultynck G, Monaco G, Parys JB, De Smedt H, Rong YP, Molitoris JK, Lam M, Ryder C, Matsuyama S, Distelhorst CW.
    Blood; 2011 Mar 10; 117(10):2924-34. PubMed ID: 21193695
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Constitutive IP3 signaling underlies the sensitivity of B-cell cancers to the Bcl-2/IP3 receptor disruptor BIRD-2.
    Bittremieux M, La Rovere RM, Akl H, Martines C, Welkenhuyzen K, Dubron K, Baes M, Janssens A, Vandenberghe P, Laurenti L, Rietdorf K, Morciano G, Pinton P, Mikoshiba K, Bootman MD, Efremov DG, De Smedt H, Parys JB, Bultynck G.
    Cell Death Differ; 2019 Mar 10; 26(3):531-547. PubMed ID: 29899382
    [Abstract] [Full Text] [Related]

  • 7. Targeting Bcl-2-IP3 receptor interaction to treat cancer: A novel approach inspired by nearly a century treating cancer with adrenal corticosteroid hormones.
    Distelhorst CW.
    Biochim Biophys Acta Mol Cell Res; 2018 Nov 10; 1865(11 Pt B):1795-1804. PubMed ID: 30053503
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor.
    Rong YP, Barr P, Yee VC, Distelhorst CW.
    Biochim Biophys Acta; 2009 Jun 10; 1793(6):971-8. PubMed ID: 19056433
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Selective regulation of IP3-receptor-mediated Ca2+ signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-Xl.
    Monaco G, Decrock E, Akl H, Ponsaerts R, Vervliet T, Luyten T, De Maeyer M, Missiaen L, Distelhorst CW, De Smedt H, Parys JB, Leybaert L, Bultynck G.
    Cell Death Differ; 2012 Feb 10; 19(2):295-309. PubMed ID: 21818117
    [Abstract] [Full Text] [Related]

  • 12. A double point mutation at residues Ile14 and Val15 of Bcl-2 uncovers a role for the BH4 domain in both protein stability and function.
    Monaco G, La Rovere R, Karamanou S, Welkenhuyzen K, Ivanova H, Vandermarliere E, Di Martile M, Del Bufalo D, De Smedt H, Parys JB, Economou A, Bultynck G.
    FEBS J; 2018 Jan 10; 285(1):127-145. PubMed ID: 29131545
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. BIRD-2, a BH4-domain-targeting peptide of Bcl-2, provokes Bax/Bak-independent cell death in B-cell cancers through mitochondrial Ca2+-dependent mPTP opening.
    Kerkhofs M, La Rovere R, Welkenhuysen K, Janssens A, Vandenberghe P, Madesh M, Parys JB, Bultynck G.
    Cell Calcium; 2021 Mar 10; 94():102333. PubMed ID: 33450506
    [Abstract] [Full Text] [Related]

  • 15. Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2's inhibition of apoptotic calcium signals.
    Rong YP, Aromolaran AS, Bultynck G, Zhong F, Li X, McColl K, Matsuyama S, Herlitze S, Roderick HL, Bootman MD, Mignery GA, Parys JB, De Smedt H, Distelhorst CW.
    Mol Cell; 2008 Jul 25; 31(2):255-65. PubMed ID: 18657507
    [Abstract] [Full Text] [Related]

  • 16. The BH4 domain of Bcl-2 orthologues from different classes of vertebrates can act as an evolutionary conserved inhibitor of IP3 receptor channels.
    Ivanova H, Luyten T, Decrock E, Vervliet T, Leybaert L, Parys JB, Bultynck G.
    Cell Calcium; 2017 Mar 25; 62():41-46. PubMed ID: 28179071
    [Abstract] [Full Text] [Related]

  • 17. Bcl-2-Protein Family as Modulators of IP3 Receptors and Other Organellar Ca2+ Channels.
    Ivanova H, Vervliet T, Monaco G, Terry LE, Rosa N, Baker MR, Parys JB, Serysheva II, Yule DI, Bultynck G.
    Cold Spring Harb Perspect Biol; 2020 Apr 01; 12(4):. PubMed ID: 31501195
    [Abstract] [Full Text] [Related]

  • 18. BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models.
    Vervloessem T, Sasi BK, Xerxa E, Karamanou S, Kale J, La Rovere RM, Chakraborty S, Sneyers F, Vogler M, Economou A, Laurenti L, Andrews DW, Efremov DG, Bultynck G.
    Cell Death Dis; 2020 Sep 17; 11(9):769. PubMed ID: 32943617
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Gold Cluster Capped with a BCL-2 Antagonistic Peptide Exerts Synergistic Antitumor Activity in Chronic Lymphocytic Leukemia Cells.
    Yao Y, Lu C, Gao L, Cao K, Yuan H, Zhang X, Gao X, Yuan Q.
    ACS Appl Mater Interfaces; 2021 May 12; 13(18):21108-21118. PubMed ID: 33942607
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.